Columbia Laboratories (CBRX) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)
Depreciation and amortization	1.44M
Amortization on beneficial conversion features
Amortization on warrant valuation
Change in value of derivative
Gain on sale of STRIANT
Change in value of redeemable warrants
Change in value of stock warrants
Recognition of deferred income
Provision for sales returns
Writeoff of accounts receivable
Writeoff of inventories
Share-based compensation
Non-cash interest expense on financing agreements
Loss on disposal of fixed assets
Accounts receivable	1.68M
Inventories	-1.22M
Prepaid expenses and other current assets	282K
Other assets	18K
Accounts payable	2.84M
Other accrued expenses
Deferred revenue	1.15M
Net cash used in operating activities
Purchase of property and equipment	-2.26M
Proceeds from sale of STRIANT
Net cash provided by (used in) investing activities
Proceeds from financing agreements
Proceeds from exercise of stock options	0
Proceeds from exercise of warrants
Payments for purchase of treasury stock
Dividends paid
Net cash provided by financing activities
EFFECT OF EXCHANGE RATE CHANGES ON CASH	-158K
NET INCREASE IN CASH	1.07M
CASH, BEGINNING OF PERIOD	13.9M
CASH, END OF PERIOD	14.97M
Interest paid	67K
Taxes paid	0
Reclassification of redeemable warrant liability to capital in excess of par
Retirement of warrant liability

Entities mentioned with CBRX

View All Entities